GenMont BiotechTPE:3164 +0.30%82 EBITDA Margin % is 46.86% as of Dec. 2025, which is 43% above its 10-year median of 32.70. GuruFocus rates TPE:3164 with a GF Score™ of 82/100 and a GF Value™ of NT$26.24 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 935 Biotechnology companies, GenMont Biotech ranks better than 90.05% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. GenMont Biotech's EBITDA for the
three
months ended in Dec. 2025 was NT$47.2 Mil. GenMont Biotech's Revenue for the
three
months ended in Dec. 2025 was NT$100.7 Mil. Therefore, GenMont Biotech's EBITDA margin for the quarter that ended in Dec. 2025 was 46.86%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
GenMont Biotech EBITDA Margin % Related Terms
GenMont Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for GenMont Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:3164 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, GenMont Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GenMont Biotech EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GenMont Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where GenMont Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenMont Biotech (TPE:3164) has a EBITDA Margin % of 46.86% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GenMont Biotech and its competitors. This is 43% above median its historical median of 32.70. Over the past decade, GenMont Biotech's EBITDA Margin % has ranged from 12.93 to 39.09. According to the industry distribution chart, GenMont Biotech ranks #93 out of 935 companies in the Biotechnology industry, placing it in the top 9.9%.
Is GenMont Biotech's EBITDA Margin % too high?
GenMont Biotech's current EBITDA Margin % of 46.86% is 43% above median its 10-year median of 32.70. Over the past 10 years, this metric has ranged from a low of 12.93 to a high of 39.09. Based on the distribution chart, GenMont Biotech ranks #93 out of 935 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, GenMont Biotech has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GenMont Biotech's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenMont Biotech ranks #93 out of 935 companies for EBITDA Margin %. This places GenMont Biotech in the top 10% of its industry — outperforming the majority of peers. Historically, GenMont Biotech's own EBITDA Margin % has ranged from 12.93 to 39.09 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GenMont Biotech and its competitors. GenMont Biotech's current EBITDA Margin % is 46.86%, which is 43% above median its own 10-year median of 32.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenMont Biotech stock overvalued right now?
Based on GuruFocus' analysis, GenMont Biotech (TPE:3164) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$26.24, compared to a current price of NT$16.55 — trading 36.9% below its estimated fair value. The current EBITDA Margin % is 46.86%, which is 43% above median its 10-year median of 32.70. GenMont Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For GenMont Biotech (TPE:3164), the current EBITDA Margin % is 46.86% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GenMont Biotech (TPE:3164) Overvalued in 2026?
Based on GuruFocus' analysis, GenMont Biotech stock appears to be undervalued.
The current stock price of NT$16.55 is trading 36.9% below its estimated GF Value™ of NT$26.24.
GuruFocus considers GenMont Biotech to be Significantly Undervalued.
Key valuation signals for TPE:3164:
EBITDA Margin %: 46.86% (43% above median its 10-year median of 32.70)
GF Value™: NT$26.24 vs. price of NT$16.55 (36.9% below fair value)
No single metric tells the full story. See the TPE:3164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenMont Biotech Inc is engaged in the research, development, manufacturing, and selling of a variety of probiotic supplements. The Group mainly engages in the manufacturing and selling of functional foods, its single operating segment.
82GF Score
Get the complete analysis for TPE:3164
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3164 has been successfully added to your 
